在中风后恢复期间,医疗保险受益人中使用 gabapentinoid
Julianne D Brooks1, Rebeka Bustamante Rocha1,2, Maria A Donahue1
1Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts.
medRxiv : the preprint server for health sciences
|August 20, 2025
概括
从2009年到2022年,医疗保险中风幸存者的 gabapentinoid 处方增加. 在美国人口普查部门观察到启动的地理差异.
科学领域:
- 老年医学 老年医学
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在弱势群体 (如老年中风幸存者) 中,对 gabapentinoid 处方趋势的研究不足.
- 在这个人口群体中描述 gabapentinoid 的使用对于理解中风后护理至关重要.
研究的目的:
- 描述急性缺血性中风 (AIS) 后医疗保险受益人中的 gabapentinoid 启动模式.
- 为了分析在中风后的 gabapentinoid 处方趋势和地理差异.
主要方法:
- 来自20%的美国医疗保险受益者 (≥65岁) 接受AIS (2009-2022) 住院治疗的样本的索赔数据分析.
- 纳入标准:传统的医疗保险入学,没有先前的中风,出院到家或住院设施 (≤30天).
- 在出院后六个月内对门诊 gabapentinoid 处方进行了分析,根据年龄,目的地标准化,并修改了 Rankin 评分.
主要成果:
- 在153,728名符合条件的医疗保险中风幸存者中,4.9%的人在出院后六个月内开始服用 gabapentinoids.
- 开始服用 gabapentinoid 的比例从 2009 年的 3.6% 增加到 2022 年的 5.8%.
- 观察到显著的地理差异,西南中部 (6.0%) 的启动率最高,新英格兰 (3.9%) 的启动率最低.
结论:
- 在美国医疗保险中风幸存者中, gabapentinoid的启动在2009年至2022年之间有所增加.
- 在美国的中风幸存者中, gabapentinoid 处方存在地理差异.
相关概念视频
01:20Antiepileptic Drugs: Potassium Channel Activators
272
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
272
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
632
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
632
01:26Peripheral Artery Disease IV: Nursing Management
42
The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
42
01:23Peripheral Artery Disease V: Postoperative Nursing Management
24
During the postoperative period, it is crucial to focus on maintaining circulation, identifying and managing potential complications, and planning for discharge.Nursing AssessmentVital signs monitoring: Regularly monitor vital signs, including blood pressure, heart rate, respiratory rate, and temperature, to detect early signs of complications such as bleeding and infection.Circulation assessment: Monitor pulses, perform Doppler assessments, and check capillary refill, color, temperature, and...
24
01:14Antiepileptic Drugs: Glutamate Antagonists
509
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
509
01:09Peripherally and Centrally Acting Muscle Relaxants: A Comparison
3.7K
Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
3.7K